Keller U - Search Results

1

A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies.

Huber K, Aichler M, Sun N, Buck A, Li Z, Fernandez IE, Hauck SM, Zitzelsberger H, Eickelberg O, Janssen KP, Keller U, Walch A. Huber K, et al. Among authors: keller u. Histochem Cell Biol. 2014 Oct;142(4):361-71. doi: 10.1007/s00418-014-1223-0. Epub 2014 May 14. Histochem Cell Biol. 2014. PMID: 24824474

2

Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.

Huber K, Feuchtinger A, Borgmann DM, Li Z, Aichler M, Hauck SM, Zitzelsberger H, Schwaiger M, Keller U, Walch A. Huber K, et al. Among authors: keller u. Anal Chem. 2014 Nov 4;86(21):10568-75. doi: 10.1021/ac502177y. Epub 2014 Oct 15. Anal Chem. 2014. PMID: 25263480

3

Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma.

Li Z, Herrmann K, Pirsig S, Philipp-Abbrederis K, Henninger M, Aichler M, Feuchtinger A, Walch A, Beer AJ, Ringshausen I, Pomykala KL, Scheidhauer K, Schwaiger M, Keller U, Buck AK. Li Z, et al. Among authors: keller u. Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):70-9. eCollection 2013. Am J Nucl Med Mol Imaging. 2013. PMID: 24380047 Free PMC article.

4

Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma.

Graf N, Li Z, Herrmann K, Weh D, Aichler M, Slawska J, Walch A, Peschel C, Schwaiger M, Buck AK, Dechow T, Keller U. Graf N, et al. Among authors: keller u. Onco Targets Ther. 2014 May 23;7:789-98. doi: 10.2147/OTT.S59314. eCollection 2014. Onco Targets Ther. 2014. PMID: 24920919 Free PMC article.

5

Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.

Jacobs L, Habringer S, Slawska J, Huber K, Hauf E, Li Z, Refaeli Y, Schwaiger M, Rudelius M, Walch A, Keller U. Jacobs L, et al. Among authors: keller u. Oncotarget. 2017 Aug 24;8(45):78917-78929. doi: 10.18632/oncotarget.20551. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108275 Free PMC article.

6

FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.

Li Z, Graf N, Herrmann K, Jünger A, Aichler M, Feuchtinger A, Baumgart A, Walch A, Peschel C, Schwaiger M, Buck A, Keller U, Dechow T. Li Z, et al. Among authors: keller u. Cancer Res. 2012 Oct 1;72(19):5014-24. doi: 10.1158/0008-5472.CAN-12-0635. Epub 2012 Aug 8. Cancer Res. 2012. PMID: 22875026

7

[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.

Graf N, Herrmann K, Numberger B, Zwisler D, Aichler M, Feuchtinger A, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, Peschel C, Schwaiger M, Keller U, Dechow T, Buck AK. Graf N, et al. Among authors: keller u. Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):34-43. doi: 10.1007/s00259-012-2255-0. Epub 2012 Oct 5. Eur J Nucl Med Mol Imaging. 2013. PMID: 23053327

8

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.

den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U. den Hollander J, et al. Among authors: keller u. Blood. 2010 Sep 2;116(9):1498-505. doi: 10.1182/blood-2009-11-251074. Epub 2010 Jun 2. Blood. 2010. PMID: 20519624 Free PMC article.

9

A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma.

Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, Scheuerer C, Peschel C, Schwaiger M, Dechow T, Keller U. Herrmann K, et al. Among authors: keller u. J Nucl Med. 2011 Dec;52(12):1898-902. doi: 10.2967/jnumed.111.094698. Epub 2011 Nov 7. J Nucl Med. 2011. PMID: 22065875 Free article. Clinical Trial.

10

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.

Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U. Philipp-Abbrederis K, et al. Among authors: keller u. EMBO Mol Med. 2015 Apr;7(4):477-87. doi: 10.15252/emmm.201404698. EMBO Mol Med. 2015. PMID: 25736399 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

960 results

Search Page

Filters